2025-09-23 - Analysis Report
Okay, here's an analysis of UnitedHealth Group Inc. (UNH) based on the data provided, structured as requested:

## UNH (UnitedHealth Group Inc.) Stock Analysis

UnitedHealth Group Inc. is a diversified health care company offering a wide range of products and services.

### 1. Performance vs. S&P 500 (VOO)

*   **UNH Cumulative Return:** 29.94%
*   **VOO Cumulative Return:** 106.97%
*   **Spread:** -76.8
*   **Spread Range:** Max: 55.3, Min: -101.4
*   **Relative Spread:** 15.7

**Analysis:** UNH has significantly underperformed the S&P 500 (VOO) over the period analyzed, with a cumulative return difference of -76.8%. The relative spread of 15.7 indicates that the current underperformance is closer to the minimum underperformance level observed in the historical data range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2015-2017  | 65.0%   | 56.6%   | 36.0%   | 0.0    | 202.4  |
| 2016-2018  | 52.0%   | 63.7%   | 34.0%   | 0.0    | 228.7  |
| 2017-2019  | 38.0%   | 63.7%   | 9.0%    | 0.3    | 269.9  |
| 2018-2020  | -21.0%  | 63.7%   | -40.0%  | 0.4    | 321.9  |
| 2019-2021  | 36.0%   | 61.0%   | -13.0%  | 0.4    | 461.0  |
| 2020-2022  | 28.0%   | 66.9%   | 26.0%   | 0.4    | 486.7  |
| 2021-2023  | 33.0%   | 67.5%   | 15.0%   | 0.4    | 483.3  |
| 2022-2024  | -31.0%  | 68.6%   | -57.0%  | 0.3    | 464.4  |
| 2023-2025  | -46.0%  | 75.7%   | -105.0% | 0.1    | 309.1  |

**Analysis of the Table:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR 변동성이 큼; 최근 2년간 상당히 저조한 수치를 보임.
*   **MDD (Maximum Drawdown):** 비교적 높은 MDD는 투자 기간 동안 상당한 손실을 경험할 수 있음을 시사.
*   **Alpha:**  알파는 시장 대비 초과 수익을 나타내는데, 최근에는 마이너스 값을 보이며 시장 수익률에 뒤쳐지고 있음.
*   **Beta:** 베타 값은 0에 가까우나 0.3~0.4 수치를 보이며, 시장 변동성에 덜 민감한 경향을 보임
*   **Cap(B) (Market Capitalization in Billions):** 전반적으로 시가총액은 증가했지만, 최근에는 감소하는 추세.

### 2. Recent Stock Price Movement

*   **Current Price:** 336.69
*   **Last Market Data:** Price: 341.3, Previous Close: 336.69, Change: 1.37
*   **5-day Moving Average:** 340.16
*   **20-day Moving Average:** 324.48
*   **60-day Moving Average:** 297.59

**Analysis:** The price increased sharply compared to previous day.The current price is slightly below the 5-day moving average but significantly above the 20-day and 60-day moving averages. This suggests a short-term pullback after a recent upward trend.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 66.85 (Approaching overbought territory)
*   **PPO:** -0.13
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-09-16)
*   **20-day Relative Spread Change:** -5.0 (Negative - Short-term Decline)
*   **Expected Return:** 34.9% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates a low-risk market environment.
*   **RSI:** Shows the stock is approaching overbought levels, suggesting a potential pullback.
*   **PPO:** The negative PPO suggests that the short-term moving average is below the long-term moving average, which can be a sign of a downward trend.
*   **Hybrid Signal:** Suggests a "Buy" signal, but with caution due to the MRI.
*   **Recent Price Change:** The last market data indicates a positive change (price: 341.3, previousClose: 336.69, change: 1.37). This is reflected in the recent news of analyst price target raises (see section 4).
*   **Expected Return:** The high expected return suggests potential long-term outperformance compared to the S&P 500 if held for 2+ years.
*   **상대이격도 변화량:** 최근 20일 동안 상대이격도가 감소했다는 것은 단기적으로 주가가 하락하고 있음을 의미.

### 4. Recent News & Significant Events

*   **Positive:**
    *   UBS Raises Price Target to $378, Maintains 'Buy' Rating.
    *   UnitedHealth Group Exceeds Market Returns (Headline, but needs to be interpreted with the underperformance data above).
    *   Optum Insight names new CEO.
*   **Negative/Neutral:**
    *   Director Sells 27 Shares.
    *   Multiple Challenges Hit UnitedHealth Group in Q2.
    *   Social Buzz: Mixed sentiment.

**Analysis:** Recent news presents a mixed picture. Analyst upgrades and a new CEO are positive, while concerns about Q2 challenges and a director selling shares raise concerns. It is important to note that while one headline claims UnitedHealth Group exceeds market returns, the performance data above suggests it is actually underperforming the S&P 500.

#### 4-2 Analyst Opinions:

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (~Buy)
*   **Opinions:** 24
*   **Target Price:** Avg: 338.33 / High: 626.00 / Low: 198.00
*   **Recent Rating Changes:** No specific information about recent changes is provided

**Analysis:** Analyst consensus indicates a 'Buy' rating, with a mean target price slightly above the current price. The wide range of target prices suggests uncertainty about the company's future performance.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-08-11 | 3.76 | 111.62 B$ |
| 2025-05-07 | 6.9  | 109.58 B$ |
| 2024-11-04 | 6.56 | 100.82 B$ |
| 2024-08-09 | 4.58 | 98.86 B$  |
| 2025-08-11 | 4.58 | 98.86 B$  |

**Analysis:**

*   매출은 전반적으로 증가하는 추세.
*   EPS는 변동성이 있으며, 최근 분기에는 감소. 2025-08-11의 EPS가 3.76으로 낮은데, 같은 날짜의 이전 기록(4.58)과 중복되어 오류가 있는지 확인 필요.
*   최근 실적 발표에서 EPS가 감소한 점은 투자자들에게 우려를 줄 수 있음.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $111.62B | 17.93%        |
| 2025-03-31 | $109.58B | 21.70%        |
| 2024-12-31 | $100.81B | 21.14%        |
| 2024-09-30 | $100.82B | 22.84%        |
| 2024-06-30 | $98.86B  | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $94.72B  | 3.60%   |
| 2025-03-31 | $95.04B  | 6.62%   |
| 2024-12-31 | $92.66B  | 5.98%   |
| 2024-09-30 | $94.53B  | 6.41%   |
| 2024-06-30 | $89.36B  | 4.72%   |

**Analysis:**

*   **Revenue:** 꾸준히 증가하는 추세.
*   **Profit Margin:** 변동성이 있으며, 최근 분기에 감소.
*   **Equity:** 전반적으로 증가하는 추세.
*   **ROE (Return on Equity):** 변동성이 있으며, 최근 분기에 감소.

### 7. 종합 분석 (Overall Analysis)

Based on the provided data, here's a summary:

*   **Performance:** UNH has significantly underperformed the S&P 500 recently.
*   **Technicals:**  The stock price is above its 20-day and 60-day moving averages, suggesting an upward trend, but RSI indicates that the stock is approaching overbought levels.
*   **Risk:** MRI indicates a low-risk market environment.
*   **News:** Recent news is mixed, with analyst upgrades offset by concerns about Q2 challenges and insider selling.
*   **Analyst Sentiment:** Analyst consensus is positive, but target prices vary widely.
*   **Earnings & Financials:** Revenue is increasing, but profit margins and ROE have declined recently.
*   **Expected Return:** Long-term expected return is high, but recent performance has been weak.

**Conclusion:**

UNH presents a mixed picture. While analyst ratings and long-term expected returns are positive, recent underperformance relative to the S&P 500, declining profit margins and ROE, and mixed news headlines suggest caution. Investors should weigh the potential for long-term outperformance against the recent challenges and underperformance. It's crucial to consider whether the current price reflects these challenges adequately and whether the company can overcome them to achieve its long-term growth potential. 또한 최근 주가 변동성이 크기 때문에 신중한 투자 결정이 필요합니다.
